Medicare Enrolled
Dr. Misagh Karimi, MD
Hematology & Oncology · Newport Beach, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Karimi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Karimi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Karimi
Dr. Misagh Karimi is a hematology & oncology specialist in Newport Beach, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Karimi performed 63,459 Medicare services across 1,409 unique beneficiaries.
Between the years covered by Open Payments, Dr. Karimi received a total of $801,755 from 60 pharmaceutical and/or device companies across 962 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Karimi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 12% volume in CA
$801,755 industry payments
Medicare Practice Summary
Medicare Utilization ↗63,459
Medicare services
Top 12% in CA for hematology & oncology
1,409
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,173 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (aprepitant) | 15,470 | $1 | $6 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
15,000 | $1 | $4 |
| Pembrolizumab injection (Keytruda) | 12,600 | $38 | $169 |
| Romosozumab injection (Evenity) for osteoporosis | 4,410 | $8 | $36 |
| Anti-nausea injection (ondansetron/Zofran) | 2,720 | $0 | $0 |
| Denosumab injection (Prolia/Xgeva) | 2,700 | $19 | $83 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
2,280 | $36 | $160 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,762 | $0 | $0 |
| Injection, leucovorin calcium, per 50 mg | 1,459 | $3 | $14 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
859 | $2 | $8 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
751 | $98 | $434 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
600 | $77 | $344 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
513 | $14 | $93 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
344 | $121 | $606 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
187 | $12 | $81 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
143 | $138 | $599 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
131 | $26 | $134 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
127 | $26 | $147 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
119 | $59 | $295 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
102 | $156 | $448 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
101 | $18 | $88 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
95 | $59 | $273 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
94 | $25 | $109 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
91 | $1 | $4 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
81 | $29 | $220 |
| New patient office visit, complex (60-74 min) | 79 | $159 | $697 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
73 | $18 | $84 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
65 | $2 | $9 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
63 | $67 | $292 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
61 | $23 | $103 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
60 | $65 | $289 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
58 | $1 | $23 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
51 | $12 | $69 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 50 | $14 | $62 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
34 | $17 | $81 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
33 | $1 | $5 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
27 | $31 | $134 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
23 | $51 | $247 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
18 | $65 | $295 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
13 | $86 | $445 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
12 | $109 | $456 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
28.8% high complexity
69.1% medium
2.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$801,755
Total received (2018-2024)
Avg $114,536/year across 7 years
Top 1% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
60
Companies
962
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$685,914 (85.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$112,372 (14.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,469 (0.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$144,126
2023
$104,067
2022
$83,846
2021
$110,819
2020
$47,445
2019
$162,978
2018
$148,475
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$33,817
EMD Serono, Inc.
$32,963
Merck Sharp & Dohme LLC
$22,184
Takeda Pharmaceuticals U.S.A., Inc.
$17,777
PFIZER INC.
$15,379
AstraZeneca Pharmaceuticals LP
$11,177
Eisai Inc.
$6,538
Exelixis Inc.
$1,620
TAIHO ONCOLOGY, INC.
$1,400
ARRAY BIOPHARMA INC
$720
Celgene Corporation
$552
Top 3 companies account for 61.7% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$192,809
Genentech USA, Inc.
$143,767
Amgen Inc.
$59,779
Merck Sharp & Dohme LLC
$55,571
AstraZeneca Pharmaceuticals LP
$54,334
Merck Sharp & Dohme Corporation
$43,057
Puma Biotechnology, Inc.
$36,823
PFIZER INC.
$34,592
EMD Serono, Inc.
$33,809
Rigel Pharmaceuticals, Inc.
$23,132
Eisai Inc.
$22,831
Takeda Pharmaceuticals U.S.A., Inc.
$21,082
Verastem, Inc.
$10,385
Seagen Inc.
$9,999
ARRAY BIOPHARMA INC
$8,454
Incyte Corporation
$6,670
GENZYME CORPORATION
$6,426
EISAI INC.
$4,552
Celgene Corporation
$4,172
Lilly USA, LLC
$4,149
Janssen Pharmaceuticals, Inc
$3,504
Karyopharm Therapeutics Inc.
$2,665
Boehringer Ingelheim International GmbH
$2,580
Heron Therapeutics, Inc.
$2,568
Astellas Pharma US Inc
$1,925
Janssen Biotech, Inc.
$1,658
Exelixis Inc.
$1,638
GlaxoSmithKline, LLC.
$1,630
G1 Therapeutics, Inc.
$1,500
Ipsen Biopharmaceuticals, Inc
$1,464
TAIHO ONCOLOGY, INC.
$1,400
Janssen Global Services, LLC
$1,362
Novocure GmbH
$250
COMSORT, Inc
$150
PharmaEssentia USA Corporation
$122
Gilead Sciences, Inc.
$118
Novartis Pharmaceuticals Corporation
$111
Blueprint Medicines Corporation
$84
PUMA BIOTECHNOLOGY, INC.
$68
Pharmacyclics LLC, An AbbVie Company
$64
SANOFI-AVENTIS U.S. LLC
$60
Bayer HealthCare Pharmaceuticals Inc.
$53
Regeneron Healthcare Solutions, Inc.
$48
Boehringer Ingelheim Pharmaceuticals, Inc.
$29
Janssen Scientific Affairs, LLC
$28
Foundation Medicine, Inc.
$25
Array BioPharma Inc.
$24
Lexicon Pharmaceuticals, Inc.
$23
Myovant Sciences Inc.
$23
JAZZ PHARMACEUTICALS INC.
$21
Alexion Pharmaceuticals, Inc.
$20
Acceleron Pharma, Inc.
$20
BeiGene USA, Inc.
$20
Dova Pharmaceuticals
$19
Alnylam Pharmaceuticals Inc.
$18
TOLMAR Pharmaceuticals, Inc.
$17
Secura Bio, Inc.
$15
AngioDynamics, Inc.
$14
Emmaus Medical, Inc.
$13
Daiichi Sankyo Inc.
$11
Top 3 companies account for 49.4% of all-time payments
Associated products mentioned in payments ›
ALIMTA · AYVAKIT · Abraxane · Alecensa · Avastin · BALVERSA · BAVENCIO · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Braftovi · CABOMETYX · CALQUENCE · CAPRELSA · COSELA · CYRAMZA · Cabometyx · Copiktra · DARZALEX · Doptelet · ELIGARD · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ERLEADA · Endari · Erleada · FARYDAK · FOUNDATIONONE · FRUZAQLA · GAVRETO · GILOTRIF · GIVLAARI · IBRANCE · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · JEVTANA · KANJINTI · KEYTRUDA · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · ONIVYDE · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · PIQRAY · POLIVY · PROMACTA · Prolia · REBLOZYL · Reblozyl · SANDOSTATIN · SARCLISA · SOMATULINE DEPOT · SUSTOL · Stivarga · TAGRISSO · TECENTRIQ · TUKYSA · Tarceva · Tavalisse · Trodelvy · ULTOMIRIS · VELCADE · VOTRIENT · Vectibix · XARELTO · XGEVA · XPOVIO · XTANDI · Xermelo · Xofigo · ZEPZELCA · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (86%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for hematology & oncology in CA.
Geographic Context
Hematology & oncology specialists within 10 mi
164
Per 100K population
5.2
County median income
$113,702
Nearest hospital
COLLEGE HOSPITAL COSTA MESA
2.8 mi
2.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Karimi is a mixed practice specialist, with above-average Medicare volume (top 12% in CA), with speaking/promotional industry engagement in the top 1% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Karimi experienced with anti-nausea injection (aprepitant)?
Based on Medicare claims data, Dr. Karimi performed 15,470 anti-nausea injection (aprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Karimi receive payments from pharmaceutical companies?
Yes. Dr. Karimi received a total of $801,755 from 60 companies across 962 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Karimi's costs compare to other hematology & oncology specialists in Newport Beach?
Dr. Karimi's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Karimi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Newport Beach
Browse hematology & oncology specialists in Newport Beach ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology